Discovery of safe and effective gene targets for cellular reprogramming therapies

发现细胞重编程疗法安全有效的基因靶点

• 批准号: 10064114
• 金额: $ 44.6万
• 依托单位: SHIFT BIOSCIENCE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10064114
• 关键词: Discovery; safe; effective; gene; targets

We are living longer, but not necessarily enjoying good health in later life. Men and women born in England in 2018-2020 can expect to live to 79.4 and 83.1 years, respectively, but will spend the last 16.3 and 19.3 years, respectively, in 'not good' health. The ageing population is already placing huge pressures on the overstretched NHS and social care services. The UK spent 7.8% of its GDP on health and care provision (2018/19); this is projected to rise to close to or above 10% of GDP by 2030/31\.Based in the Milner Therapeutics Institute (Cambridge Biomedical Campus), Shift Bioscience is a biotech start-up cofounded by CEO Dr Daniel Ives (PhD University of Cambridge), CSO Dr Brendan Swain (PhD University of Cambridge), and CFO Steve Ives (serial Cambridge-based entrepreneur). Our ambition is to deliver the first drugs for safe cellular rejuvenation, ultimately preventing age-related functional decline, improving healthy life expectancy for patients, and reducing the ageing burden on health and care service providers.Situated at the leading-edge of biomedical science, Shift Bioscience has developed a patent-pending machine learning methodology that enables us to untangle the cellular rejuvenation pathway and identify gene targets for safe rejuvenation. With Smart funding, we will further develop and refine our game-changing platform technology, performing 3 experimental cycles to discover safe gene targets. Successful project outcomes will unlock clinical development of world-changing rejuvenation therapies by allowing us to negotiate Pharma partnerships.Our innovation aligns with three priority areas of UK strength and opportunity highlighted in UK Innovation Strategy 2021 (AI; Bioinformatics and genomics; and, Engineering Biology) and supports two Industrial Strategy Challenge Fund areas (developing leading-edge healthcare for the Ageing Society, exploiting AI and data), while directly supporting the UK's mission to address the underlying biology of ageing highlighted within the UK Life Sciences Vision 2021\.

我们活得更长了，但在晚年并不一定享有良好的健康。2018-2020年出生在英国的男性和女性的预期寿命分别为79.4岁和83.1岁，但在最后16.3岁和19.3岁期间，他们的健康状况分别不佳。人口老龄化已经给不堪重负的NHS和社会护理服务带来了巨大压力。英国在医疗保健方面的支出占GDP的7.8%(2018/19年)；预计到2030/31年，这一比例将上升至接近或超过GDP的10%。Shift Bioscience是一家生物技术初创公司，由首席执行官丹尼尔·艾夫斯博士(剑桥博士)、首席财务官布伦丹·斯温博士(剑桥博士)和首席财务官史蒂夫·艾夫斯(剑桥大学连续创业者)共同创立。我们的目标是提供第一批用于安全细胞再生的药物，最终防止与年龄相关的功能衰退，提高患者的健康预期寿命，并减轻健康和护理服务提供者的老龄化负担。Shift Bioscience处于生物医学科学的前沿，开发了一种正在申请专利的机器学习方法，使我们能够解开细胞再生途径的纠缠，并确定安全再生的基因目标。有了Smart Funding，我们将进一步开发和完善我们改变游戏规则的平台技术，执行3个实验周期来发现安全的基因靶点。成功的项目成果将使我们能够谈判医药合作伙伴关系，从而开启改变世界的年轻化疗法的临床开发。我们的创新与英国创新战略2021中强调的三个优先领域(人工智能；生物信息学和基因组学；以及工程生物学)保持一致，并支持两个产业战略挑战基金领域(为老龄化社会发展尖端医疗保健，利用人工智能和数据)，同时直接支持英国的使命，解决英国生命科学愿景2021年强调的潜在衰老生物学问题。